NeoImmuneTech Revenue Surges on Endari Sales, but Net Loss Continues

Consolidated Q1 2026 revenue surged to $0.53M (vs $0.01M in Q1 2025), first recognition of Endari service revenue of $0.29M
Net loss narrowed to $5.15M (vs $5.72M), operating loss improved to $4.24M (vs $8.08M)
Cash and cash equivalents $35.2M (down $3.7M from year-end 2025), quarterly operating cash flow -$5.57M
R&D expenses decreased 25% YoY to $2.61M, cost efficiency efforts
Lead asset NT-I7 in Phase 2 trials and ARS primate studies; ongoing collaboration with Merck
Convertible bond balance KRW 10B (conversion price KRW 3,080), potential dilution risk
Voluntarily withdrew Roche collaboration for NSCLC in April 2026 (negative)
New CEO Kim Tae-kyung appointed, granted 200,000 stock options